Joanna M Rhodes1, Vincent A LoRe2, Anthony R Mato3, Elise A Chong4, Jacqueline C Barrientos5, James N Gerson4, Stefan K Barta4, Daniel J Landsburg4, Sunita Dwivedy Nasta4, Jakub Svoboda4, Alison W Loren4, Stephen J Schuster4. 1. Division of Hematology/Oncology, Northwell Health Cancer Institute, New Hyde Park, NY; Division of Hematology/Oncology, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA. Electronic address: Jrhodes3@northwell.edu. 2. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA. 3. Chronic Lymphocytic Leukemia Program, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Division of Hematology/Oncology, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA. 5. Division of Hematology/Oncology, Northwell Health Cancer Institute, New Hyde Park, NY.
Abstract
INTRODUCTION: The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has transformed the treatment of chronic lymphocytic leukemia (CLL), leading to unprecedented improvements in progression-free and overall survival for all patients, including those with poor prognostic features. The side effect profile of ibrutinib is unique compared with chemoimmunotherapy and includes atrial fibrillation, increased bleeding risk, and arthralgias/myalgias. Although common, arthralgias/myalgias and their management are poorly described. PATIENTS AND METHODS: We identified 214 patients with CLL treated with ibrutinib (as a single agent or in combination) from 2011 to 2018 at the University of Pennsylvania. RESULTS: In this cohort, 36% (76/214) of patients developed arthralgias/myalgias during follow-up with a median onset of 34.5 months. Most (79%) events were grade 1 or 2. Risk factors for developing arthralgias/myalgias included younger age at start of ibrutinib, female gender, and ibrutinib use as first treatment. Twenty-eight percent of patients with grade 1 or 2 toxicity continued ibrutinib and had resolution of symptoms. Dose holds were frequently used to manage this toxicity, and this strategy was more successful than dose reduction. Sixty-two percent of patients with grade 3 toxicity ultimately discontinued ibrutinib. Supportive care measures such as discontinuing statins or use of non-steroidal anti-inflammatory drugs, acetaminophen, or corticosteroids were not used frequently enough in this cohort to evaluate their efficacy. CONCLUSIONS: Additional studies to determine the mechanism of ibrutinib-related arthralgias/myalgias are needed to develop optimal management strategies.
INTRODUCTION: The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has transformed the treatment of chronic lymphocytic leukemia (CLL), leading to unprecedented improvements in progression-free and overall survival for all patients, including those with poor prognostic features. The side effect profile of ibrutinib is unique compared with chemoimmunotherapy and includes atrial fibrillation, increased bleeding risk, and arthralgias/myalgias. Although common, arthralgias/myalgias and their management are poorly described. PATIENTS AND METHODS: We identified 214 patients with CLL treated with ibrutinib (as a single agent or in combination) from 2011 to 2018 at the University of Pennsylvania. RESULTS: In this cohort, 36% (76/214) of patients developed arthralgias/myalgias during follow-up with a median onset of 34.5 months. Most (79%) events were grade 1 or 2. Risk factors for developing arthralgias/myalgias included younger age at start of ibrutinib, female gender, and ibrutinib use as first treatment. Twenty-eight percent of patients with grade 1 or 2 toxicity continued ibrutinib and had resolution of symptoms. Dose holds were frequently used to manage this toxicity, and this strategy was more successful than dose reduction. Sixty-two percent of patients with grade 3 toxicity ultimately discontinued ibrutinib. Supportive care measures such as discontinuing statins or use of non-steroidal anti-inflammatory drugs, acetaminophen, or corticosteroids were not used frequently enough in this cohort to evaluate their efficacy. CONCLUSIONS: Additional studies to determine the mechanism of ibrutinib-related arthralgias/myalgias are needed to develop optimal management strategies.
Authors: Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Weiqiang Zhao; Allison M Booth; Wei Ding; Nancy L Bartlett; Danielle M Brander; Paul M Barr; Kerry A Rogers; Sameer A Parikh; Steven Coutre; Arti Hurria; Jennifer R Brown; Gerard Lozanski; James S Blachly; Hatice G Ozer; Brittny Major-Elechi; Briant Fruth; Sreenivasa Nattam; Richard A Larson; Harry Erba; Mark Litzow; Carolyn Owen; Charles Kuzma; Jeremy S Abramson; Richard F Little; Scott E Smith; Richard M Stone; Sumithra J Mandrekar; John C Byrd Journal: N Engl J Med Date: 2018-12-01 Impact factor: 91.245
Authors: Susan O'Brien; Jeffrey A Jones; Steven E Coutre; Anthony R Mato; Peter Hillmen; Constantine Tam; Anders Österborg; Tanya Siddiqi; Michael J Thirman; Richard R Furman; Osman Ilhan; Michael J Keating; Timothy G Call; Jennifer R Brown; Michelle Stevens-Brogan; Yunfeng Li; Fong Clow; Danelle F James; Alvina D Chu; Michael Hallek; Stephan Stilgenbauer Journal: Lancet Oncol Date: 2016-09-13 Impact factor: 41.316
Authors: Asher Chanan-Khan; Paula Cramer; Fatih Demirkan; Graeme Fraser; Rodrigo Santucci Silva; Sebastian Grosicki; Aleksander Pristupa; Ann Janssens; Jiri Mayer; Nancy L Bartlett; Marie-Sarah Dilhuydy; Halyna Pylypenko; Javier Loscertales; Abraham Avigdor; Simon Rule; Diego Villa; Olga Samoilova; Panagiots Panagiotidis; Andre Goy; Anthony Mato; Miguel A Pavlovsky; Claes Karlsson; Michelle Mahler; Mariya Salman; Steven Sun; Charles Phelps; Sriram Balasubramanian; Angela Howes; Michael Hallek Journal: Lancet Oncol Date: 2015-12-05 Impact factor: 41.316
Authors: Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillermo Dighiero; Hartmut Döhner; Peter Hillmen; Michael Keating; Emili Montserrat; Nicholas Chiorazzi; Stephan Stilgenbauer; Kanti R Rai; John C Byrd; Barbara Eichhorst; Susan O'Brien; Tadeusz Robak; John F Seymour; Thomas J Kipps Journal: Blood Date: 2018-03-14 Impact factor: 22.113
Authors: Carol Moreno; Richard Greil; Fatih Demirkan; Alessandra Tedeschi; Bertrand Anz; Loree Larratt; Martin Simkovic; Olga Samoilova; Jan Novak; Dina Ben-Yehuda; Vladimir Strugov; Devinder Gill; John G Gribben; Emily Hsu; Chih-Jian Lih; Cathy Zhou; Fong Clow; Danelle F James; Lori Styles; Ian W Flinn Journal: Lancet Oncol Date: 2018-12-03 Impact factor: 41.316
Authors: A R Mato; B T Hill; N Lamanna; P M Barr; C S Ujjani; D M Brander; C Howlett; A P Skarbnik; B D Cheson; C S Zent; J J Pu; P Kiselev; K Foon; J Lenhart; S Henick Bachow; A M Winter; A-L Cruz; D F Claxton; A Goy; C Daniel; K Isaac; K H Kennard; C Timlin; M Fanning; L Gashonia; M Yacur; J Svoboda; S J Schuster; C Nabhan Journal: Ann Oncol Date: 2017-05-01 Impact factor: 32.976
Authors: John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen Journal: N Engl J Med Date: 2014-05-31 Impact factor: 91.245
Authors: Jennifer R Brown; Javid Moslehi; Susan O'Brien; Paolo Ghia; Peter Hillmen; Florence Cymbalista; Tait D Shanafelt; Graeme Fraser; Simon Rule; Thomas J Kipps; Steven Coutre; Marie-Sarah Dilhuydy; Paula Cramer; Alessandra Tedeschi; Ulrich Jaeger; Martin Dreyling; John C Byrd; Angela Howes; Michael Todd; Jessica Vermeulen; Danelle F James; Fong Clow; Lori Styles; Rudy Valentino; Mark Wildgust; Michelle Mahler; Jan A Burger Journal: Haematologica Date: 2017-07-27 Impact factor: 9.941